BLPH Bellerophon Therapeutics Inc.

1.08
-0.06  -5%
Previous Close 1.14
Open 1.14
Price To Book 15.43
Market Cap 63373851
Shares 58,679,492
Volume 236,665
Short Ratio
Av. Daily Volume 281,899

SEC filingsSee all SEC filings

  1. 8-K - Current report 181164812
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181164793
  3. 8-K - Current report 181135331
  4. 8-K - Current report 181123563
  5. 8-K - Current report 181112293

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line Cohort 1 data due January 2019 with Cohort 2 and 3 data due later in 2019.
INOpulse delivery device
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)
Phase 3 trial stopped due to futility - August 7, 2018.
INOpulse delivery device
Pulmonary Arterial Hypertension (PAH)
Phase 2 trial met primary endpoint - noted September 5, 2017.
INOpulse delivery device
Pulmonary Hypertension associated with COPD (PH-COPD)
Phase 2 trial to be initiated YE 2018 with data due 2019.
INOpulse delivery device
Pulmonary hypertension associated with Sarcoidosis (PH-Sarcoidosis)

SEC Filings

  1. 8-K - Current report 181164812
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181164793
  3. 8-K - Current report 181135331
  4. 8-K - Current report 181123563
  5. 8-K - Current report 181112293
  6. 8-K - Current report 181089508
  7. 8-K - Current report 181053943
  8. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181026724
  9. 8-K - Current report 181009951
  10. 8-K - Current report 18996395